DOVA - ドバ・ファ―マシュ―ティカルズ (Dova Pharmaceuticals Inc.) ドバ・ファ―マシュ―ティカルズ

 DOVAのチャート


 DOVAの企業情報

symbol DOVA
会社名 Dova Pharmaceuticals Inc (ドバ・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 ドバ・ファーマシューティカルズ(Dova Pharmaceuticals Inc.)は臨床段階の製薬会社である。同社は、医薬品候補の取得・開発・商品化に従事する。最初の焦点は、低血小板数を特徴とする障害である血小板減少症である。同社は、慢性肝疾患(CLD)患者の血小板減少症の治療のためにアバトロンボパグを開発している。同社の製品候補であるアバットロボパッグは、経口投与されたトロンボポエチン受容体アゴニスト、またはTPO-RAである。同社は、CLD患者の血小板減少症の治療用アバトロンボパグを評価する第3相臨床試験を完了した。同社はいかなる収益も生じていない。   ドバ・ファ―マシュ―ティカルズはアメリカの製薬会社。主に、血小板の数値が低い血小板減少症の治療薬の開発・商業化に従事する。同社パイプラインには血小板の前駆細胞の増殖や分化に関与する造血因子のトロンボポエチン受容体作動薬であるアボトロンボパグ「TPO-RA」が含まれている。本社所在地はノ―スカロライナ州ダ―ラム。   Dova Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical company, which engages in the acquisition, development and commercialization of drug candidates for rare diseases. It focuses on addressing thrombocytopenia, a disorder characterized by a low blood platelet count. Its drug candidate includes avatrombopag, an orally administered thrombopoietin receptor agonist. The company was founded on March 24, 2016 and is headquartered in Durham, NC.
本社所在地 240 Leigh Farm Road Suite 245 Durham NC 27707 USA
代表者氏名 Paul B. Manning ポール・B・マニング
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 919-806-4487
設立年月日 42430
市場名 NASDAQ National Market System
ipoyear 2017年
従業員数 33人
url www.dova.com
nasdaq_url https://www.nasdaq.com/symbol/dova
adr_tso
EBITDA EBITDA(百万ドル) -51.45600
終値(lastsale) 20.45
時価総額(marketcap) 576736339.7
時価総額 時価総額(百万ドル) 566.01950
売上高 売上高(百万ドル) 4.58400
企業価値(EV) 企業価値(EV)(百万ドル) 451.47450
当期純利益 当期純利益(百万ドル) -52.45100
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Dova Pharmaceuticals Inc revenues increased from $0K to $4.6M. Net loss increased from $10.9M to $33.4M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Interest Exp-Net of Capitalized increase of 48% to $769K (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.44 to -$1.22.

 DOVAのテクニカル分析


 DOVAのニュース

   Dova Pharmaceuticals Enters Overbought Territory: Is A Drop Coming?  2019/10/24 15:40:00 Zacks Investment Research
Dova Pharmaceuticals has moved higher as of late, but there could definitely be trouble on the horizon for this company.
   Dova Pharmaceuticals rallies on buyout offer from Swedish Orphan Biovitrum  2019/09/30 11:10:00 MarketWatch
Dova Pharmaceuticals shares climbed 37% to $27.75 a share in premarket trade after Swedish Orphan Biovitrum said it will buy the company for $27.50 a share…
   Dova Pharmaceuticals (DOVA) Jumps: Stock Rises 8.8%  2019/09/25 12:34:00 Zacks Investment Research
Dova Pharmaceuticals (DOVA) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
   Dova Pharmaceuticals (DOVA) Reports Q2 Loss, Lags Revenue Estimates  2019/08/06 13:35:06 Zacks Investment Research
Dova Pharmaceuticals (DOVA) delivered earnings and revenue surprises of -5.26% and -37.55%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
   Dova Pharmaceuticals (DOVA) in Focus: Stock Moves 9.1% Higher  2019/07/05 14:09:00 Zacks Investment Research
Dova Pharmaceuticals (DOVA) shares rose more than 9% in the last trading session, amid huge volumes.
   Dova Pharmaceuticals Enters Overbought Territory: Is A Drop Coming?  2019/10/24 15:40:00 Zacks Investment Research
Dova Pharmaceuticals has moved higher as of late, but there could definitely be trouble on the horizon for this company.
   Dova Pharmaceuticals rallies on buyout offer from Swedish Orphan Biovitrum  2019/09/30 11:10:00 MarketWatch
Dova Pharmaceuticals shares climbed 37% to $27.75 a share in premarket trade after Swedish Orphan Biovitrum said it will buy the company for $27.50 a share…
   Dova Pharmaceuticals (DOVA) Jumps: Stock Rises 8.8%  2019/09/25 12:34:00 Zacks Investment Research
Dova Pharmaceuticals (DOVA) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
   Dova Pharmaceuticals (DOVA) Reports Q2 Loss, Lags Revenue Estimates  2019/08/06 13:35:06 Zacks Investment Research
Dova Pharmaceuticals (DOVA) delivered earnings and revenue surprises of -5.26% and -37.55%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
   Dova Pharmaceuticals (DOVA) in Focus: Stock Moves 9.1% Higher  2019/07/05 14:09:00 Zacks Investment Research
Dova Pharmaceuticals (DOVA) shares rose more than 9% in the last trading session, amid huge volumes.
   Dova Pharmaceuticals Enters Overbought Territory: Is A Drop Coming?  2019/10/24 15:40:00 Zacks Investment Research
Dova Pharmaceuticals has moved higher as of late, but there could definitely be trouble on the horizon for this company.
   Dova Pharmaceuticals rallies on buyout offer from Swedish Orphan Biovitrum  2019/09/30 11:10:00 MarketWatch
Dova Pharmaceuticals shares climbed 37% to $27.75 a share in premarket trade after Swedish Orphan Biovitrum said it will buy the company for $27.50 a share…
   Dova Pharmaceuticals (DOVA) Jumps: Stock Rises 8.8%  2019/09/25 12:34:00 Zacks Investment Research
Dova Pharmaceuticals (DOVA) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
   Dova Pharmaceuticals (DOVA) Reports Q2 Loss, Lags Revenue Estimates  2019/08/06 13:35:06 Zacks Investment Research
Dova Pharmaceuticals (DOVA) delivered earnings and revenue surprises of -5.26% and -37.55%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
   Dova Pharmaceuticals (DOVA) in Focus: Stock Moves 9.1% Higher  2019/07/05 14:09:00 Zacks Investment Research
Dova Pharmaceuticals (DOVA) shares rose more than 9% in the last trading session, amid huge volumes.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ドバ・ファ―マシュ―ティカルズ DOVA Dova Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)